Details for New Drug Application (NDA): 215270
✉ Email this page to a colleague
NDA 215270 describes METHYLTESTOSTERONE, which is a drug marketed by Heather, Impax Labs Inc, Novitium Pharma, Impax Labs, Lilly, Purepac Pharm, Pvt Form, Tablicaps, Usl Pharma, Inwood Labs, Kv Pharm, Lannett, Parke Davis, Watson Labs, and West Ward, and is included in twenty-eight NDAs. It is available from two suppliers. Additional details are available on the METHYLTESTOSTERONE profile page.
The generic ingredient in METHYLTESTOSTERONE is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
The generic ingredient in METHYLTESTOSTERONE is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.
Summary for 215270
| Tradename: | METHYLTESTOSTERONE |
| Applicant: | Novitium Pharma |
| Ingredient: | methyltestosterone |
| Patents: | 0 |
Pharmacology for NDA: 215270
| Mechanism of Action | Androgen Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 215270
Suppliers and Packaging for NDA: 215270
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| METHYLTESTOSTERONE | methyltestosterone | CAPSULE;ORAL | 215270 | ANDA | Novitium Pharma LLC | 70954-255 | 70954-255-10 | 100 CAPSULE in 1 BOTTLE (70954-255-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Feb 18, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
